Editorial

Structural diversity is the most important fundamental in the modern drug discovery program. Every structural type, in principal, is capable of locking a particular disease mechanism. Everyday in various laboratories of the world, thousands of structurally diverse compounds are synthesized or isolated from natural sources. This structural diversity, if properly harnessed, can lead to breakthrough discoveries and improve, currently dismal, efficiency in drug development. One of the reasons why combinatorial chemistry has not been as successful as expected in delivering the novel molecular entities, is inherently the low structural diversity of resulting synthetic libraries. Medicinal chemists and other researchers involved in drug discovery programs, therefore always look for novel structural leads with potential to be used against specific biological targets. The quarterly journal, “Current Bioactive Compounds (CBC)”, thus provides an important first set of information for drug discovery scientists. We are glad that the journal has been very well received globally and has already achieved a substantial subscription base in the last two years. Along with easy-to-read directory of newly discovered bioactive compounds, in-depth selected reviews on various classes of bioactive compounds have also been included in this issue of CBC. These reviews, contributed by leading scientists in their fields, focus on structures and mechanisms of action of various classes most important of bioactive chemical compounds against a range of most important of biological disorders. At the end, we wish to acknowledge the contributions of the dedicated editorial and secretarial staff of the Bentham Science Publishers. Notable among them are Mr. Mahmood Alam (Director Publications) and his team, Dr. Ziaullah, Miss Samreen Laeeq and Mr. Ansar Ahmed Qadri.